In The News
GenomeWeb | January 17, 2018
Fresh off a $74 million initial public offering, Quanterix is looking to make immediate inroads in the biotech and pharma research space with longer-term plans to move into diagnostics and health monitoring.
Medical Device and Diagnostic Industry | January 16, 2018
Would you rather get a biopsy or a blood test to check for prostate cancer?
Genetic Engineering & Biotechnology News | January 15, 2018
New technology has shown promise for detecting CTE and the approximately 150 protein biomarkers linked to conditions in neurology, oncology, cardiology, inflammation, and infectious disease. Called Simoa™, it is a single-molecule array on a fully automated digital immunoassay platform that detects…
January 12, 2018
Presentation led by Kevin Hrusovsky, President, Chairman and CEO Quanterix Presentation Date: Wednesday, January 10, 2018
The Wall Street Journal | December 08, 2017
Biomarker-analysis company had raised venture capital from ARCH Venture Partners, Bain
Cheddar.com | December 08, 2017
Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share.